|drug471||Blood collection Wiki||1.00|
|drug2836||Remote Problem Management Plus Wiki||1.00|
|drug2998||Saliva collection Wiki||0.41|
There is one clinical trial.
COVID-19 is a pathology linked to the SARS-CoV-2 virus, a new virus of the coronaviridae family that emerged in China in December 2019 before rapidly becoming a pandemic according to the WHO on March 11, 2020. The epidemic affected France from February 2020. On February 24, a patient hospitalized at Percy hospital was the cause of a major nosocomial epidemic, potentially responsible for more than 250 symptomatic people in the hospital as of April 6. The outbreak was identified by Percy hospital management on March 16, and barrier measures were immediately put in place. From March 20, a mixed investigation unit set up a chain of nasopharyngeal swabs for Percy hospital staff. A COVID-19 case reporting unit was set up at Percy hospital in response to the identification of the outbreak within the hospital. This unit carried out rapid identification and regular follow-up until the return to work of the staff. Thus all symptomatic patients are identified and the COVID-19 case census cell will follow all Percy hospital staff, including volunteers recruited to deal with the epidemic, throughout the duration of the epidemic. This population, captive by nature, will be one of the few described in the world during this epidemic. Current data on short-, medium- and long-term immunity induced by COVID-19 infection are fragmentary, as is the existence of a large asymptomatic population, making it difficult to cut the chains of transmission in the absence of an effective diagnostic tool. Another important issue is the quality of immunity induced by the infection, as it conditions the future of the pandemic, which could become endemic and recurrent if immunity were not sterilizing. As yet unpublished data in primates show that in the primate model re-infection is not possible in the short term, while patients cured from the Wuhan epidemic seem to be detected again positive for virus shedding. The objective of this study is to characterize the immunity (systemic and local) induced by SARS-Cov-2 infection among Percy hospital staff who are at high risk of contamination even in a period of confinement.
Description: The presence of induced immunity will be identified by an Ig family switch on the first two serologies with a high titre of specific IgG and disappearance of IgM.Measure: Induced SARS-CoV2 immunity Time: At day 21 (compared to enrollment [Day 0])
Description: The presence of induced immunity will be identified on serology analysis at 6 months.Measure: Long-term protection of induced SARS-CoV2 immunity at 6 months Time: 6 months following enrollment
Description: The presence of induced immunity will be identified on serology analysis at 1 year.Measure: Long-term protection of induced SARS-CoV2 immunity at 1 year Time: 1 year following enrollment
Description: Kinetics of anti-SARS-CoV-2 antibodies using ELISA technique on serum samples from enrollment (Day 0) to 1 year after enrollementMeasure: Anti-SARS-CoV2 antibodies kinetics in blood throughout the study Time: From enrollment (Day 0) to 1 year after enrollement
Description: Kinetics of anti-SARS-CoV-2 antibodies using ELISA technique on saliva samples from enrollment (Day 0) to 1 year after enrollementMeasure: Anti-SARS-CoV2 antibodies kinetics in saliva throughout the study Time: From enrollment (Day 0) to 1 year after enrollement
Description: Kinetics of serum neutralization against SARS-CoV-2 positive using ELISA technique on serum samples from enrollment (Day 0) to 1 year after enrollement.Measure: Kinetics of serum neutralization in blood throughout the study Time: From enrollment (Day 0) to 1 year after enrollement
Description: Anti-SARS-Cov2 seroprevalence measured in serum samples collected at Day 0.Measure: Anti-SARS-CoV2 seroprevalence in asymptomatic individuals at Day 0 Time: At enrollment (Day 0)
Description: Anti-SARS-Cov2 seroprevalence measured in serum samples collected at Day 21.Measure: Anti-SARS-CoV2 seroprevalence in asymptomatic individuals at Day 21 Time: At Day 21
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports